Oragenics Inc (OGEN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oragenics Inc   (NYSE: OGEN)


Oragenics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Oragenics Inc 's ROA in the second quarter of 2026?
Oragenics Inc recorded a cumulative net loss of $-10 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -112.8%.

However, within the Healthcare sector 760 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4333, from total ROA ranking in the first quarter of 2026 at 5053.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 67.77 % 93.58 % 385.77 % 148.48 % 25 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -10 -10 -10 -11 -10
Return On Assets (TTM) -112.8 % -117.21 % -131.6 % -198.98 % -287.56 %
OGEN's Total Ranking # 4333 # 5053 # 4618 # 4762 # 4833
Total Assets (TTM) in million 5 7 10 13 3
Seq. Total Assets Change -26.67 % -25.61 % -20.76 % 288.1 % -15.39 %
Seq. Net Income Change - - - - -

OGEN's 5 Years Annual ROA >> Back to OGEN Management Effectiveness >> Compare OGEN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 352
Sector # 761
Overall # 4266

Return On Assets Statistics
High Average Low
-44.61 %
-140.86 %
-765.85 %
(Dec 31 2014)   (Jun 30 2012)



  News about Oragenics Inc Return on Assets ROA

Oragenics, Inc.: Trailblazing Neurological Solutions with Strategic Vision,

Oragenics, Inc.: Pioneering Neurological Therapeutics Amidst a New Strategic VisionIn the rapidly evolving landscape of biotechnology, few companies have displayed the agility and foresight necessary to adapt and innovate as effectively as Oragenics, Inc. The Sarasota-based biotechnology firm has taken notable strides under the leadership of CEO Janet Huffman, making significant advancements in the treatment of neurological disorders. In its recent Q1 2025 shareholder update, the company not only highlighted its financial progress but also underscored the momentum of its lead candidate, ONP-002, which is set to advance into a pivotal Phase IIa concussion trial.As the global focus on neurological health intensifies, driven by increasing incidences of conditions such as concussions, Alzheimer s, and other cognitive disorders, the importance of research and development in this field has never been more pronounced. Oragenics stands at the forefront, cultivating an innovative biomarker-driven approach to expedite the discovery and clinical development of therapeutics aimed at treating these debilitating conditions.



Financial Statements
Oragenics Inc 's Assets $ 5 million OGEN's Balance sheet
Oragenics Inc 's Income $ -3 million Quarterly OGEN's Income Statement
OGEN's Income by Division See OGEN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 583.71 % -69.74 % -66.23 % -48.08 % -50.72 %
Total Assets in million 10 1 5 14 28
Y / Y Net Income Change - - - - -
Net Income in million -10 -11 -21 -14 -16
Annual Return On Assets -97.76 % -717.68 % -424.51 % -99.15 % -56.61 %

OGEN's 5 Years Annual ROA >> Back to OGEN Management Effectiveness >> Compare OGEN ROA to its Competitors



More Return On Assets Ratios
OGEN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OGEN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OGEN's Competitors
Subscribers only: Roa for Oragenics Inc 's Suppliers
Subscribers only: Return On Assets for OGEN's Customers

You may also want to know
OGEN's Roi OGEN's Inventory Turnover Ratio OGEN's Growth Rates OGEN's Dividend Comparisons
OGEN's Profitability Ratios OGEN's Asset Turnover Ratio OGEN's Dividend Growth
OGEN's Roe OGEN's Valuation Ratios OGEN's Financial Strength Ratios OGEN's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-03T12:05:26+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.